Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants by Caroline A. Browne & Irwin Lucki
REVIEW ARTICLE
published: 27 December 2013
doi: 10.3389/fphar.2013.00161
Antidepressant effects of ketamine: mechanisms
underlying fast-acting novel antidepressants
Caroline A. Browne1 and Irwin Lucki1,2*
1 Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
2 Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
Edited by:
Maarten Van Den Buuse, Mental
Health Research Institute, Australia
Reviewed by:
Charles H. Large, Autifony
Therapeutics Limited, Italy
Kenji Hashimoto, Chiba University
Center for Forensic Mental Health,
Japan
*Correspondence:
Irwin Lucki, Department of
Psychiatry, University of
Pennsylvania, 125 South 31st
Street, Room 2204, Philadelphia, PA
19104-3404, USA
e-mail: lucki@mail.med.upenn.edu
Newer antidepressants are needed for the many individuals with major depressive
disorder (MDD) that do not respond adequately to treatment and because of a delay
of weeks before the emergence of therapeutic effects. Recent evidence from clinical
trials shows that the NMDA antagonist ketamine is a revolutionary novel antidepressant
because it acts rapidly and is effective for treatment-resistant patients. A single infusion
of ketamine alleviates depressive symptoms in treatment-resistant depressed patients
within hours and these effects may be sustained for up to 2 weeks. Although
the discovery of ketamine’s effects has reshaped drug discovery for antidepressants,
the psychotomimetic properties of this compound limit the use of this therapy to the
most severely ill patients. In order to develop additional antidepressants like ketamine,
adequate preclinical behavioral screening paradigms for fast-acting antidepressants need
to be established and used to identify the underlying neural mechanisms. This review
examines the preclinical literature attempting to model the antidepressant-like effects of
ketamine. Acute administration of ketamine has produced effects in behavioral screens for
antidepressants like the forced swim test, novelty suppression of feeding and in rodent
models for depression. Protracted behavioral effects of ketamine have been reported to
appear after a single treatment that last for days. This temporal pattern is similar to its
clinical effects and may serve as a new animal paradigm for rapid antidepressant effects
in humans. In addition, protracted changes in molecules mediating synaptic plasticity
have been implicated in mediating the antidepressant-like behavioral effects of ketamine.
Current preclinical studies are examining compounds with more specific pharmacological
effects at glutamate receptors and synapses in order to develop additional rapidly acting
antidepressants without the hallucinogenic side effects or abuse potential of ketamine.
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INTRODUCTION
Major depressive disorder (MDD) is a serious public health
problem and one of the most common psychiatric disorders,
with a lifetime prevalence of 17% in the United States (Kessler
et al., 2005). Although the currently available antidepressants
provide a measurable degree of therapy, approximately 50% of
individuals diagnosed with MDD do not respond adequately to
first–line treatment with conventional antidepressants (Trivedi
et al., 2006; Fava et al., 2008). Moreover, the 3–4 week delay
in the onset of therapeutic efficacy is particularly difficult for
patients with persistent suicidal ideation. Patients that emerge
as treatment resistant, defined as failing two or more trials of
medication, are more severely ill with comorbid anxiety disor-
ders and are at increased risk of suicide for an extended period
of time (Joffe et al., 1993; Souery et al., 2007; Schosser et al.,
2012). Therefore, there is a pressing medical need to develop
rapidly acting therapeutics that are capable of immediately reliev-
ing the depressive symptomology, and persisting in their action as
an antidepressant, for patients unable to respond to conventional
therapies.
Recently it has been demonstrated that the NMDA receptor
antagonist ketamine has rapid-acting and transient antidepres-
sant effects in patients that are treatment resistant (Mathew
et al., 2012). However, the discovery of ketamine is no panacea.
The psychotomimetic properties and abuse potential of ketamine
necessitate caution in promoting this particular compound as
a general treatment for MDD. Understanding the underlying
mechanism of action of ketamine linked to behavioral improve-
ment is of significant importance for the development of novel,
more improved antidepressants beyond the use of ketamine.
This review will focus on the molecular alterations and animal
behavior studies that have been used to measure potential cor-
relates of the antidepressant effects of ketamine. As ketamine
produces clinical antidepressant effects with a different time
course and apparently different neurochemical mechanism than
conventional antidepressants, the results of these studies have
revealed new paradigms that can be used to identify novel
compounds which may have a similar therapeutic potential
and time course as ketamine in targeting treatment resistant
depression (TRD).
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KETAMINE—CLINICAL TRIALS
The initial clinical trials were double blind crossover studies that
utilized a single infusion of ketamine (0.5mg/kg) administered
intravenously over a 40min period (Berman et al., 2000; Zarate
et al., 2006). Berman et al reported decreases in depressive symp-
tomology, which emerged progressively over the first 3 days in all
of the eight patients that were treated; one patient continued to
show antidepressant-like effects 2 weeks post-infusion. Similarly,
Zarate and colleagues reported a significant and rapid alleviation
of depressive symptoms in 12 individuals on the first day, with six
subjects exhibiting symptom alleviation for a least 1 week; two of
these subjects continued to show antidepressant effects 2 weeks
post-single ketamine infusion. Subsequent studies reported sig-
nificant efficacy of ketamine in reducing suicidal ideation in indi-
viduals exhibiting TRD (Diazgranados et al., 2010). Moreover,
a proof of concept trial conducted in treatment-resistant bipo-
lar patients revealed a more rapid onset of antidepressant effects
following ketamine infusion concomitant to their valproate and
lithium treatment compared to previous studies conducted in
MDD patients. However, the alleviation of depressive symp-
toms in the bipolar study persisted for only 3 days compared
to the 7 days reported in earlier trials. In addition, ketamine
had significant efficacy in patients resistant to electroconvulsive
therapy (ECT) and produced more rapid antidepressant effects
compared to ECT (Ibrahim et al., 2011). Unlike the almost imme-
diate alleviation of depressive symptomology associated with
ketamine infusion, similar reductions in symptoms were observed
approximately 1–2 weeks following the first of the thrice-weekly
ECT exposures. Furthermore, the use of ketamine as the anes-
thetic prior to ECT has been suggested to improve outcome and
response to ECT (Hoyer et al., 2013). Indeed, the administration
of ketamine/propofol (ketofol) improved the severity of seizure
duration, induced an earlier onset of the antidepressant effect
and significantly improved cognitive performances compared to
propofol (Wang et al., 2012). Recently, it was reported that sub-
anesthetic doses of S-ketamine with propofol actually worsened
the post-treatment disorientation in some patients (Jarventausta
et al., 2013). Further research is ongoing to determine the benefit
of the S-enantiomer over the commonly used racemic mixture of
ketamine. One group suggested that S-ketamine did not induce
the transient psychotomimetic effects evident in the initial phase
of infusion (Segmiller et al., 2013).
An extensive clinical trial involving 67 patients at two
sites with documented TRD established the most definitive
antidepressant efficacy of ketamine, in comparison with the
benzodiazepine, midazolam, used as an active placebo con-
trol (Murrough et al., 2013). The response rates to ketamine
vs. midazolam were 64 and 28%, respectively, with ketamine
significantly reducing scores in the MADRS by 7.95 points.
Ketamine-treated patients continued to exhibit improved scores
over the 7-day period post-infusion compared to midazolam,
however, the reduction of depressive scores on day 7 was no
longer significant. Although most studies of ketamine have
involved only a small number of patients, this is the best-
designed and most extensive clinical trial to confirm the efficacy
of ketamine in rapidly and persistently alleviating depressive
symptomology.
Because the clinical effects of ketamine are transient, studies
have assessed the efficacy of ketamine administration when given
chronically. Significant improvement of symptoms persisted fol-
lowing six infusions of ketamine over 11 days, although the 9
patients treated in this trial eventually relapsed 19 days after the
final infusion (aan het Rot et al., 2010). In addition, the effects
of oral administration of ketamine given over a long-term period
yielded positive findings, with patients exhibiting improvedmood
over the 28-day treatment period. Interestingly, although the level
of symptom alleviation was the same as that achieved by I.V.
infusion of ketamine, oral ketamine did not elicit a significant
effect on depressive symptoms until day 14 of treatment but for-
tunately did relieve anxiety symptoms within 3 days of treatment
(Irwin et al., 2013). Psychotomimetic effects were not observed
in these patients; however, there were some reports of sleep dis-
turbances and diarrhea. Moreover, another study conducted in
bipolar patients using sublingual ketamine indicated significant
(70%) numbers of individuals exhibiting improved mood with
limited side effects with rapid onset of action. These data indicate
that further evaluation of the administration route of ketamine
and their side effect profiles may be beneficial.
Although there is a clear consensus on the rapidity of the
antidepressant effect of ketamine in TRD, with most patients
experiencing elevated mood starting approximately 120min
post-infusion, not all patients respond to ketamine treatment.
Response rates across studies have ranged between 25 and 85%
at 24 h and 14–70% at 72 h (Aan Het Rot et al., 2012). In addi-
tion, the duration of the antidepressant effect has varied across
studies. In most of the trials conducted so far, only approximately
half of the patients exhibited relief of depressive symptoms from
ketamine lasting past 72 h. The reasons underlying variability in
the response to ketamine are unknown. Given the heterogeneous
nature of depression, a number of genetic, environmental and
patient characteristics may be associated with treatment response.
For example, patients with a family history of alcohol use disorder
(AUD) exhibit better outcomes in response to ketamine adminis-
tration, reporting less psychotomimetic disturbances and greater
reductions of depression symptoms, compared to MDD patients
without a history of AUD (Phelps et al., 2009). In addition, poten-
tial biomarkers or genetic variants will likely be found to augment
or prevent responsiveness to ketamine.
Some clinical studies have tried to identify the critical phar-
macological characteristics of ketamine associated with treatment
response. Modification of the NMDA receptor subunit NR2Bmay
confer an increased treatment response; indeed, NR2B antago-
nists, CP-1016060 and MK-0657 have shown good efficacy in
treating TRD patients (Preskorn et al., 2008; Ibrahim et al.,
2012a). AZD6765, a NMDA channel blocker, was assessed for
its antidepressant-like qualities in a double blind crossover study
involving 22 subjects. Although no psychotomimetic effects of
this compound were reported, depressive symptoms were alle-
viated only for the first 2 h following infusion (Zarate et al.,
2013). Similarly, administration of riluzole, (a sodium chan-
nel blocker, which indirectly inhibits glutamate release) for 4
weeks following ketamine infusion did not potentiate symptom
improvement compared to placebo (Ibrahim et al., 2012b). These
reports and a growing literature indicate that the mechanisms of
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action mediating ketamine’s antidepressant effects have not yet
been identified and are not elicited simply by the blockade of
NMDA receptors.
ANTIDEPRESSANT-LIKE BEHAVIORAL EFFECTS OF
KETAMINE IN RODENTS
The ability of ketamine to affect depressive-like behavior in
a number of preclinical behavioral paradigms and models of
depression has been widely studied in the past few years. Many
reports indicate that acute administration of ketamine produces
antidepressant-like effects in rodents (Table 1). However, some of
the findings have not been replicated consistently by other labo-
ratories. The literature concerning the antidepressant-like effects
of ketamine is reviewed here, focusing on the effects of varying
test conditions on behavioral outcomes. In addition, many studies
have now reported that the effects of a single dose of ketamine can
bemeasured over a protracted period of time lasting between days
to weeks (Table 2). The time course of these protracted effects
resembles the time course for ketamine’s clinical effects (Yilmaz
et al., 2002; Maeng et al., 2008), and may represent a new ani-
mal behavioral paradigm that correlates with the clinical effects
of rapidly acting antidepressants.
FORCED SWIM TEST (FST)
The FST is the most frequently used behavioral test for measuring
depressive-like behavior in rodents. It has also been a frequently
used test within the preclinical ketamine literature. Mice and rats
placed in cylinders containing water rapidly become immobile,
demonstrated by floating passively or making only movements
necessary to remain afloat. Based on an immobility response
induced by inescapable exposure to stress, the FST also has strong
predictive validity because short-term administration of antide-
pressant compounds from a variety of pharmacological classes
reduces immobility time in the FST. These drugs include tricyclic
compounds, MAO inhibitors, atypical antidepressants, and SSRIs
(Cryan et al., 2005). Furthermore, the behavioral effects of tri-
cyclics and SSRIs do not last beyond a few hours following their
acute administration (Hoshaw et al., 2008).
Several groups have reported that a single administration of
ketamine produced acute reductions of immobility in the FST
shortly after injection (Table 1). Although the majority of these
studies utilized a 10mg/kg dose administered intraperitoneally
(i.p.), subanesthetic doses of ketamine ranging from 10–50mg/kg
have produced antidepressant-like effects in the FST. However,
some studies failed to detect acute effects of ketamine using the
FST inmice (Bechtholt-Gompf et al., 2011) or in rats (Popik et al.,
2008).
A feature of ketamine’s pharmacology distinct from conven-
tional antidepressants is that it produces protracted behavioral
effects persisting between one to several days after administration
(Table 2). The majority of studies indicate that the FST remains
sensitive to the protracted effects of ketamine up to 1 week after a
single injection (Table 1). These protracted effects were reported
to persist for 8 days (Ma et al., 2013), 10 days (Yilmaz et al.,
2002), 12 days (Garcia et al., 2008a), and 2 weeks (Maeng et al.,
2008). Interestingly, antidepressant-like effects of ketamine were
observed in the FST 2 months following the cessation of a 15-day
treatment of rats during adolescence (Parise et al., 2013). This
result is in line with other studies that have used a 10 or 12-
day dosing regimen to establish longer-lasting effects of chronic
ketamine on depressive-like activity in the FST (Tizabi et al.,
2012; Akinfiresoye and Tizabi, 2013). Only one study examin-
ing the protracted effects of ketamine failed to report this finding
(Lindholm et al., 2012).
The presence of chronic stress has been shown to facilitate the
detection of antidepressant-like effects of ketamine in the FST
(Koike et al., 2013a). There are also significant strain differences
in the sensitivity to ketamine. For example, Wistar rats are insen-
sitive to the antidepressant-like effects of low dose ketamine (2.5
and 5mg/kg) following chronic treatment. In contrast, WKY rats
were extremely sensitive to ketamine-induced reductions in FST
immobility (Tizabi et al., 2012). WKY rats have a high baseline
immobility level in the FST, which may allow for a greater sen-
sitivity to compounds. Moreover, WKY rats are a genetic model
of pathological depression and anxiety (Will et al., 2003; Solberg
et al., 2004), which could provide them greater sensitivity to the
effects of ketamine. Finally, the WKY strain is insensitive to SSRIs
(Lopez-Rubalcava and Lucki, 2000; Tejani-Butt et al., 2003; Will
et al., 2003) showing that ketamine is active under conditions
where current antidepressants are ineffective. This feature makes
WKY rats a useful strain in which to assess novel compounds
resembling ketamine, which may be screened for efficacy in TRD.
TAIL SUSPENSION TEST (TST)
The TST is widely used in the preclinical ketamine literature as a
less stressful test of behavioral despair when mice are suspended
from their tail (Steru et al., 1985; Cryan et al., 2005). TST has pre-
dictive validity because it measures antidepressant-like responses
from various classes of drugs. Ketamine reduces immobility levels
in mice acutely, with studies reporting reductions in immobility
time at 30min (Mantovani et al., 2003; Rosa et al., 2003; Cruz
et al., 2009; Koike et al., 2011a) and 24 h (Koike et al., 2011b)
following a single injection of ketamine.
The most effective dose in the TST was 30mg/kg. ICR mice
were particularly sensitive to ketamine and continued to exhibit
decreased immobility 72 h after treatment (Koike et al., 2011b).
Furthermore, a lower dose of ketamine (10mg/kg) was effective in
reducing TST immobility increased by chronic mild stress (CMS)
48 h after ketamine injection (Ma et al., 2013). In contrast, two
studies indicated that the acute reduction in immobility by high
dose ketamine (50 and 160mg/kg) was not maintained 1 week
following treatment in mice (Popik et al., 2008; Bechtholt-Gompf
et al., 2011). These data suggest that the TST is most valuable in
the assessment of the more immediate antidepressant effects of
ketamine. However, exposure to stress could increase the sensi-
tivity to ketamine in the TST. To date there are no studies that
have investigated whether the TST is sensitive to a chronic dosing
regimen of ketamine.
NOVELTY SUPPRESSED FEEDING (NSF)
Exposure to a novel environment produces an anxiety-like phe-
notype in rodents known as hyponeophagia. In the NSF and
novelty-induced hypophagia (NIH) tests, the latency to feed is
increased and the amount of food consumption is reduced in a
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Table 1 | Acute effects of ketamine.
References Species and strain Ketamine—supplier
and dose
Behavioral alterations Molecular alterations
ACUTE EFFECTS OF KETAMINE
Burgdorf
et al., 2013
Male adult (2–3
months)
Sprague-Dawley rats
Fort Dodge (Butler,
USA), I.V., I.P., and S.C.
10mg/kg
Reduced immobility in FST 20–60min
and 24 h post i.p. Injection (10mg/kg).
Reduced latency to feed in the NIH 1h
post 10mg/kg i.v.
Increased NR2B and GluR1
expression in the mPFC and
HC 24h post-injection
Carrier and
Kabbaj, 2013
Male (250–270 g)
and female
(200–225 g)
Sprague-Dawley rats
Fort Dodge (Butler
Schein), Inc.
2.5–0mg/kg
Latency to feed was reduced in the NSF
24h post-injection (5 and 10mg/kg).
Increased sucrose consumption of
males 48 h post-injection in the SPT.
Reduced immobility in FST in males &
females 30min post-injection
Increased mTOR
phosphorylation in males
and females, reduced eEF2
phosphorylation in males
(5mg/kg)
Gigliucci
et al., 2013
Male (280–320 g)
Sprague- Dawley rats
Vetoquinol Ltd., UK
(1.0mg/ml). 10–25mg/kg
i.p.
Rats exhibited antidepressant-like
effects in the FST at 1 or 24 h after a
single injection of ketamine. Ketamine
was ineffective following 3 injections
(24, 5 and 1 h prior to testing). Ketamine
(25mg/kg) reversed stress-induced
immobility; this was prevented by pCPA
treatment at 24 h but not at 1 h
post-injection
Depletion of cortical
serotonin levels by pCPA
(1.0mg/kg once daily for 3
days) attenuated the
antidepressant-like effect of
ketamine in the FST
Koike et al.,
2013a
Male
Sprague-Dawley rats
(185–325 g at
testing)
Ketalar® Sankyo Yell
Pharmaceutical Co.,
Ltd., 1–10mg/kg i.p.
Ketamine (10mg/kg) decreased
immobility 30min post-treatment in rats
exposed to 21 days of corticosterone
administration
N/A
Koike et al.,
2013b
Male ICR (5 weeks)
and male C57BL/6j
(9 weeks)
Ketalar® Sankyo Yell
Pharmaceutical Co., Ltd.
30mg/kg i.p.
Ketamine decreased immobility in the
FST & latency to feed in the NSF at
30min and 24 h post-injection.
K252a prevented ketamine’s effects at
24 h.
N/A
Muller et al.,
2013
Male Sprague
Dawley rats
(330–400 g)
Fort-Dodge (Pfizer CT),
USA. 15mg/kg (i.p.)
Reduced immobility in FST 2 h
post-injection
Increased p-αCamKII and
decreased SNARE complex
expression 1– 4 h
post-injection. No effect on
GSK-3 activity. Protracted
increased in synapsin
expression1 h to 7 days
post-injection
Walker et al.,
2013
CD-1 mice (6 wks.
old) and C57BL/6J
mice (12 weeks old)
Fort Dodge Animal
Health 6mg/kg (i.p.)
Ketamine co-administered with LPS but
not pretreatment 24 h prior blocked
LPS-induced immobility in FST and
anhedonia in the SPT. 10 h post LPS,
ketamine administration reversed the
anhedonia in SPT, this was blocked by
NBQX
Ketamine did not block the
LPS-induced increases in
kynurenine metabolites,
cytokines or BDNF
expression at 6–28 h
Iijima et al.,
2012
C57Bl/6J mice (9
weeks)
Sigma-Aldrich 30mg/kg
(i.p.)
Latency to feed in the NSF was reduced
at 30min and 24 h post-injection.
Rapamycin reversed the 24 h reduction
in NSF latency
N/A
(Continued)
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Table 1 | Continued
References Species and strain Ketamine—supplier
and dose
Behavioral alterations Molecular alterations
Liu et al.,
2012
BDNF knockin mice,
(Val66Met SNP)
Val/Met, Met/Met
and Val/Val (WT) 6–8
months
Hospira Inc. 10mg/kg
(i.p.)
24 h post-injection the AD effects of
ketamine in the FST were blocked in
Met/Met mice
Met/Met knockin mice are
insensitive to the molecular
effects of ketamine on
spine head diameter and
spine length modulated in
WT mice
Yang et al.,
2012
Male Wistar rats
(180–220 g)
Gutian Pharmaceutical
CO. Ltd., Fuijan, China
10mg/kg (i.p.)
Reduced immobility in FST 30min
post-injection
Increased mTOR
phosphorylation in HC and
PFC
Yang et al.,
2013b
Male Wistar rats
(200–300 g)
Gutian Pharmaceutical
CO. Ltd., Fuijan, China
5–15mg/kg (i.p.)
Dose-dependent reduction in immobility
in the FST 30min post-injection
Increased BDNF levels in
the HC following 10 and
15mg/kg. Dose dependent
increase in phosphorylated
mTOR levels in HC
Wang et al.,
2011
Male Wistar rats (60
days old)
Sigma-Aldrich 15mg/kg
(i.p.)
Decreased immobility in the FST 60min
post-injection
Increased BDNF expression
and decreased
phosphorylation of GluR1
(Ser845) in HC 60min
post-injection
Beurel et al.,
2011
WT and GSK-3 Knock
in mice
10mg/kg (i.p.) AD effects in LH in WT but not GSK-3
knock-in mice
Increased pGSK-3β (CTX
and HC) 30 and 60min
post-injection
Koike et al.,
2011a
Male ICR mice
(25–35 g)
Sigma-Aldrich
3–30mg/kg (i.p.)
Ketamine reduced immobility in the TST
24 h post 30mg/kg injection. Rapamycin
reversed the ketamine-induced
reduction in TST immobility
N/A
Reus et al.,
2011
Male Wistar rats (60
days old)
Fort Dodge Animal
Health—0.1 g/ml
injectable solution,
5–10mg/kg
Immobility in the FST was reduced at
60min postinjection by 10mg/kg only
Ketamine 5mg/kg
increased the expression of
BDNF, CREB, and PKC
phosphorylation in the PFC.
5mg/kg increased BDNF in
the HC and Amg. 10mg/kg
decreased BDNF in the
PFC, HC, and Amg.
10mg/kg increased CREB
expression and PKC
phosphorylation in the PFC
Li et al., 2010 Male Sprague
Dawley rats
(150–250 g)
Sigma-Aldrich 10mg/kg
(i.p.)
Ketamine produced AD effects in the
FST, LH and NSF test 24 h post-injection,
blocked by rapamycin
Ketamine 10mg/kg
activated mTOR, ERK, and
PKB/Akt signaling, blocked
by NBQX, Ketamine
10mg/kg increased
expression of certain
synaptic proteins at 2, 6,
and 72 h post-injection,
blocked by rapamycin
Ghasemi
et al., 2010
Male NMRI mice
(23–30 g)
Sigma-Aldrich
0.5–5mg/kg (i.p)
Ketamine reduced immobility in the FST
45min post-injection (2 and 5mg/kg)
N/A
Cruz et al.,
2009
Male Swiss mice
(25–35 g)
Sigma-Aldrich
6.35–50mg/kg (i.p.)
12.5, 25, and 50mg/kg ketamine
reduced immobility in the FST 30min
N/A
(Continued)
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Table 1 | Continued
References Species and strain Ketamine—supplier
and dose
Behavioral alterations Molecular alterations
post-injection. Only 50mg/kg ketamine
reduced immobility in the TST
Engin et al.,
2009
Male
Sprague-Dawley rats
(180–360 g)
10–50mg/kg (i.p.) Ketamine (50mg/kg) increased the % of
open arm entries in the EPM. Both
doses decreased immobility in the FST
30min post-injection
N/A
Rezin et al.,
2009
Male Wistar rats
(300 g)
Fort Dodge Animal
Health 15mg/kg (i.p.)
Ketamine did not reverse the
CMS-induced reduction in consumption
of sweet food
Ketamine reversed the
CMS-induced reductions in
mitochondrial respiratory
chain enzymes
Garcia et al.,
2008a
Male Wistar rats (60
days old)
Fort Dodge (Brazil) 5, 10,
and 15mg/kg (i.p.)
1 h post-injection ketamine (5 &
10mg/kg) significantly reduced
immobility in the FST
BDNF increased in the HC
following ketamine injection
(15mg/kg)
Hayase et al.,
2006
Male ICR mice
(60–90 days old)
Sankyo Co., Ltd. Tokyo,
Japan 30–1.0mg/kg (i.p.)
Ketamine increased the latency to
immobility in the FST and was anxiolytic
in the EPM at both doses 60 and
120min post-injection
N/A
Rosa et al.,
2003
Swiss mice male and
female (30–40 g)
Sigma-Aldrich 5mg/kg
(i.p.)
Ketamine reduced immobility in the TST
30min post-injection
N/A
Mantovani
et al., 2003
Male Swiss mice
35–45 g)
0.1mg/kg (i.p.) Ketamine reduced immobility in the TST
30min post-injection
N/A
This table outlines studies that have assessed the antidepressant-like effects of ketamine at 30min to 24 h post-administration in commonly used behavioral
tests. Molecular alterations of relevance to ketamine’s molecular mechanism of action are also reported. FST, forced swim test; TST, tail suspension test; LH,
learned helplessness; NSF, novelty suppressed feeding; SPT, sucrose preference test; EPM, elevated plus maze; AD, antidepressant; CMS, chronic mild stress; LPS,
lipopolysaccharide; HC, hippocampus; CTX, cortex; Amg, amygdala; mPFC, medial prefrontal cortex; WT, wild type.
novel environment. These tests, based on a similar principle, dif-
fer in methodology; NSF requires acute food deprivation 24 h
prior to testing whereas the NIH utilizes an 8–10-day training
period without deprivation. These tests have considerable face
validity, although interpretation of results with the NSF may be
limited by the use of food deprivation. Hyponeophagia is one
of the few anxiety-related tests that are reliably attenuated fol-
lowing chronic, but not acute, administration of antidepressant
drugs (Bodnoff et al., 1988; Dulawa and Hen, 2005). In contrast,
ketamine reduced the latency to eat within hours of treatment.
The effective dose range for ketamine in this task varied across
studies: 30min and 24 h following 5–10mg/kg (Li et al., 2010;
Carrier and Kabbaj, 2013) and 30mg/kg (Iijima et al., 2012), but
all tests resulted in a significant reduction in the latency to feed
in the novel environment. Moreover, ketamine (10mg/kg) suc-
cessfully reduced the latency to eat in the NIH 1 h post-injection
(Burgdorf et al., 2013). More protracted effects of acute ketamine
treatment (3mg/kg) were observed 48 h following treatment in
mice exposed to chronic stress, although ketamine did not reduce
feeding latency in stress naïve mice in this study (Autry et al.,
2011).
Overall, these data suggest that hyponeophagia is highly sensi-
tive to a single dose of ketamine, although additional parameters
of these tests remain to be examined more systematically. The
fact that ketamine produced anxiolytic effects rapidly whereas
conventional antidepressants require chronic treatment for weeks
agrees with a more rapid onset of clinical effects. As TRD
patients exhibit increased comorbid anxiety compared to treat-
ment responsive MDD patients, the usefulness of assessing
ketamine in anxiety tests should not be overlooked.
SUCROSE PREFERENCE TEST (SPT)
Sucrose consumption is widely accepted as a measure of anhedo-
nia in rodents and has significant face validity in terms of its sen-
sitivity to chronic stress and antidepressant treatment. Repeated
administration of ketamine (7 days) reversed the decrease in
sucrose consumption in rats exposed to chronic stress. Although
it should be noted that this dosing regimen with ketamine also
increased sweet food consumption in both stressed and non-
stressed rats (Garcia et al., 2009). Furthermore, administration
of a low dose of ketamine (0.5mg/kg) for 10 days significantly
increased sucrose consumption in WKY rats (Akinfiresoye and
Tizabi, 2013). Marked increases in sucrose consumption in rats
persisted at 1, 3, 5, and 7 days after a single treatment with
ketamine (10mg/kg) (Li et al., 2011), indicating significant pro-
tracted effects of ketamine on this behavior.
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Table 2 | Protracted effects of ketamine.
References Species and strain Ketamine—supplier
and dose
Behavioral alterations Molecular alterations
PROTRACTED EFFECTS OF KETAMINE
Akinfiresoye
and Tizabi,
2013
Male WKY rats Fort-Dodge (Henry
Schien), 0.25 and
0.5mg/kg (i.p.),
administered daily for
10 days
Only chronic administration of
0.5mg/kg reduced immobility
in the FST and increased
sucrose intake in the SPT
0.25mg/kg ketamine did not alter mTOR
phosphorylation or synapsin 1 and BDNF
expression
Liu et al., 2013 Male Sprague-Dawley
rats (150–250 g)
Hospira Inc., 1 and
10mg/kg (i.p.)
Ketamine reduced immobility
in the FST 24h and 1 week
following a single 10mg/kg
injection. This effect was not
observed 2 weeks
post-injection
Ketamine increased p- S6K, p-ERK, p-Akt
but not p-mTOR or GSK-3b 1 h
post-injection (10mg/kg). These changes
were not detected 24 h post-injection.
5-HT and hypocretin induced EPSCs were
increased 24 h following ketamine
treatment (10mg/kg). Ketamine 1 and
10mg/kg increased spine head diameter
and spine density
Ma et al.,
2013
C57Bl/6J mice (7 wks.
old 20 g)
Gutian Pharmaceutical
CO. Ltd., Fuijan, China.
10mg/kg (i.p.)
Ketamine reversed
CMS-induced increases in
immobility in the FST and TST
48 h post-treatment.
Ketamine reversed
CMS-induced reductions in
sucrose intake in the SPT,
24 h, 4, 6, and 8 days
post-treatment. In
non-stressed animals
ketamine reduced immobility
in the TST and FST at 3 and
24 h post-injection
N/A
Parise et al.,
2013
Male adolescent
Sprague-Dawley rats
(post-natal day 35–49)
Fort-Dodge (Schein), 5,
10, and 20mg/kg (i.p.).
Administered twice a day
for either 1 or 15 days
Ketamine (10 and 20mg/kg)
reduced immobility in the FST
24 h after the 2nd injection.
CMS-induced immobility was
reversed by ketamine
(20mg/kg). No effect of
ketamine on SPT was
observed. Two months after
chronic ketamine treatment
rats exhibited an anxiolytic
phenotype on the EPM and
AD effects in the FST
N/A
Lindholm
et al., 2012
Adult male C57Bl/6J
and WT & BDNF ±
mice
Sigma-Aldrich 20 and
50mg/kg (i.p.)
Decreased immobility in FST
in WT mice at 45min but not
7 days post-injection
No alterations in TrkB phosphorylation at
60min or 7 days post-injection
Tizabi et al.,
2012
Male and Female WKY
and Wistar rats
Fort-Dodge (Schein),
0.25–5mg/kg (i.p.),
administered once or
daily for 10 days
No acute/chronic effect of
ketamine on Wistar
immobility levels in the FST.
2.5 and 5mg/kg reduced
immobility of WKY rats in the
FST; the 5mg/kg dose had
protracted effects 1 week
post-injection. Chronic
administration of 2.5 and
Ketamine (chronic 0.5mg/kg paradigm)
increased AMPA receptor binding & the
AMPA/NMDA ration in WKY rats
(Continued)
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Table 2 | Continued
References Species and strain Ketamine—supplier
and dose
Behavioral alterations Molecular alterations
5mg/kg reduced immobility
of WKY but not Wistar. The
effect of the 2.5mg.kg dose
were evident 1 week
following the cessation of
treatment
Autry et al.,
2011
Adult male C57BL/6
WT and inducible BDNF
KO mutants
Fort Dodge Animal
Health 3mg/kg (i.p.)
No effect in EPM or fear
conditioning 24 h
post-injection. Reduced FST
immobility at 30min, 3 h,
24 h, and 1 week, blocked by
NBQX.
Reduced latency to feed in
NSF, increased sucrose intake
& decreased immobility in
CMS mice 30min
post-injection. Rapamycin did
not block ketamine-induced
reductions in FST immobility
30min post-injection.
Anisomycin prevented the
effects of ketamine in the
NSF & FST. TrkB KO mice did
not response to ketamine
Increased TrkB activation. Increased BDNF
protein but not mRNA at 30min and 1 h
post-injection. Decreased phosphorylation
of eEF2 in HC. Blocked spontaneous
activity of NMDARs in HC cultures
Bechtholt-
Gompf et al.,
2011
CD-1 and BALB/c mice Sigma-Aldrich, dose
range 0.5–3.0mg/kg
Reduced immobility in TST
1h post-injection (1.0mg/kg),
not observed at day 7. No
effect on FST immobility at
any dose, or time point
N/A
Koike et al.,
2011b
Male ICR mice
(25–35 g) and male
Sprague-Dawley rats
(230–350 g)
Sigma-Aldrich
3–30mg/kg (i.p.)
Ketamine reduced the
number of failures to escape
in the LH test 30min post
10mg/kg injection. Reduced
immobility in the TST 30min
& 72h post 30mg/kg
injection
N/A
Li et al., 2011 Male Sprague Dawley
rats (150–250 g)
Sigma-Aldrich 10mg/kg
(i.p.)
Ketamine reversed
CMS-induced anhedonia in
the NSF test 2 days
post-injection. Sucrose
consumption was increased
1, 3, 5, and 7 days following
the single ketamine injection
Ketamine reversed CMS-induced deficits
in synaptic EPSCs, spine density and
synaptic protein expression. At 7 days
post-treatment these effects were still
apparent
Yilmaz et al.,
2002)
Male Wistar rats
(280–310 g)
Parke-Davis 50mg/ml
stock 1.0mg/kg (i.p.)
Ketamine reduced FST at 3, 7,
and 10 days post-injection,
(this was only in the second
test of each day).
N/A
Garcia et al.,
2009
Wistar rats (300–350 g) Fort Dodge Animal
Health 15mg/kg once on
day 7 or daily for 7 days
CMS-induced reductions in
sucrose intake, weight loss,
adrenal hypertrophy, and
No differences in HC BDNF concentrations
(Continued)
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Table 2 | Continued
References Species and strain Ketamine—supplier
and dose
Behavioral alterations Molecular alterations
increased ACTH and
corticosterone levels were
reversed by acute and chronic
ketamine administration.
Chronic ketamine increased
sucrose intake in controls
Garcia et al.,
2008b
Wistar rats (300–350 g) Fort Dodge Animal
Health, 5, 10, and
15mg/kg—daily i.p.
injections for 12 days
All doses reduced immobility
in the FST
HC BDNF concentrations were not altered
Popik et al.,
2008
Male Wistar rats (270 g)
and male Sprague
Dawley rats (275 g),
C57/Bl/Han male mice
(24 g) and Male Swiss
mice (28 g)
Biowet, Pulawy, Poland,
FST rats, 1.0mg/kg. TST
mice, 50–1.0mg/kg. FST
mice, 1.25–10mg/kg
Reduction of immobility in
the FST in mice but not in
rats at 30min post-injection
only (50mg/kg). Ketamine
reduced immobility in the
TST at 40min but not at 1
week post-injection
N/A
Maeng et al.,
2008
Mice Sigma-Aldrich
0.5–10mg/kg (i.p.)
Ketamine reduced the
number of escape failures in
LH 24h post-injection.
Ketamine (2.5mg/kg)
reduced immobility in the
FST at 30min and 2 weeks
post-injection
Ketamine reduced phosphorylation of HC
GluR1 (S845), rescued by NBQX
This table outlines studies that have assessed the antidepressant-like effects of ketamine from day 2, or, 48 h post-administration onwards in commonly used
behavioral tests. In some of these studies earlier time points have been assessed, the results are also included in this table. Molecular alterations of relevance to
ketamine’s molecular mechanism of action are also reported. FST, forced swim test; TST, tail suspension test; LH, learned helplessness; NSF, novelty suppressed
feeding; SPT, sucrose preference test; EPM, elevated plus maze; AD, antidepressant; CMS, chronic mild stress; LPS, lipopolysaccharide; HC, hippocampus; CTX,
cortex; Amg, amygdala; mPFC, medial prefrontal cortex; WTm, wild type.
Decreases in sucrose consumption induced by exposure to LPS
(Walker et al., 2013) and CMS (Ma et al., 2013) were reversed
following a single ketamine treatment. Protracted effects of acute
ketamine treatment were evident in CMS exposed mice tested at
4, 6, and 8 days after a single ketamine treatment (Ma et al., 2013).
In contrast, the consumption of sugar pellets in CMS exposed
rats was not altered by ketamine treatment (Rezin et al., 2009),
although this particular test is not directly comparable to the tra-
ditional SPT. It should be noted that there is a lack of consensus
on the most appropriate SPT protocol to model an anhedonic
state in rats. Nevertheless, these data support the use of the SPT
as a sensitive screening test for rapid-acting antidepressant-like
drugs such as ketamine.
ELEVATED PLUS MAZE (EPM)
The EPM is frequently used to measure anxiety behavior in
rodents (Bourin, 1997; Rodgers et al., 1997) and has strong pre-
dictive validity for screening anxiolytics. However, it is generally
not sensitive to antidepressant treatments. Ketamine induced an
anxiolytic phenotype in rats during exposure to the EPM 30min
after a single ketamine injection (Engin et al., 2009). A similar
effect was observed in mice 1 and 2 h following treatment (Hayase
et al., 2006). These studies indicate that the EPM was not sen-
sitive to low doses of ketamine; only higher doses (30mg/kg)
induced a significant anxiolytic effect. Moreover, lower doses of
ketamine did not induce an anxiolytic response in the EPM in
stress naïve mice (Autry et al., 2011). The lack of effect of low
doses of ketamine is also characteristic of the TST. Parise and
colleagues described significant anxiolytic effects in the EPM in
rats 2 months after the completion of a 15-day dosing regimen
of 20mg/kg per day during adolescence (Parise et al., 2013).
Although the presence of drug effects after such a long interval
could indicate sensitivity to the protracted effects of ketamine,
developmental factors may have played a greater role. At present
the EPM can only be proposed as a tool for assessing the more
immediate anxiolytic effects of ketamine.
LOCOMOTOR ACTIVITY
Antidepressant-like effects of ketamine are usually evaluated in
conjunction with spontaneous activity, because increased motor
activity can produce false positive effects in the aforementioned
behavioral tasks. Ketamine produces significant hyperactivity
immediately following injection; 10min post i.p. injection of
low dose ketamine (5–15mg/kg), rats displayed hyperactivity in
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spontaneous activity (da Silva et al., 2010). In addition, repeated
administration of ketamine (50mg/kg) sensitized rats to its
hyperactive effects (Popik et al., 2008).
However, most studies have reported either no change or a
reduction of locomotor activity after ketamine. A reduction of
open field behavior was produced by ketamine in rats at 30min
post 50mg/kg (Engin et al., 2009) and 1 h post 10 and 25mg/kg
(Gigliucci et al., 2013). In addition, a single injection of ketamine
did not alter locomotor activity beyond 30min post-injection
in rats (Reus et al., 2011; Tizabi et al., 2012; Yang et al., 2012;
Akinfiresoye and Tizabi, 2013) or in mice (Lindholm et al., 2012).
At 24 h post-injection, there was no effect on locomotor activity in
mice by ketamine or by the NMDA antagonists CPP and MK-801
(Autry et al., 2011).
Furthermore, chronic administration of low dose ketamine did
not affect spontaneous activity in adult rats (Garcia et al., 2008b;
Ma et al., 2013). Interestingly, it was shown recently that hyper-
activity was displayed in adolescent but not adult rats following
chronic ketamine administration (Parise et al., 2013). Many of the
experiments assessed in this review did not measure the effects of
ketamine on locomotor activity at the dose and time point used.
However, taken together, the data suggest it is important practice
to assess changes in activity measures post-treatment to identify
and eliminate the involvement of any potential locomotor effect
in the behavioral responses to ketamine.
LEARNED HELPLESSNESS (LH)
The LH model of depression produces escape deficits in rodents
exposed to unpredictable and uncontrollable stress (Seligman
et al., 1980). LH is a popular model of depression as it has good
face validity and induces a number of endophenotypes that can
be measured in other behavioral tasks, including the FST and
NSF. Repeated treatment with antidepressants reversed the cop-
ing behavior deficits in rats and mice (Shanks and Anisman,
1988; Caldarone et al., 2000). A single administration of ketamine
(10mg/kg) has been reported to reverse the deficits in cop-
ing behavior induced by learned helplessness 30–60min (Beurel
et al., 2011; Koike et al., 2011a) and 24 h after treatment (Maeng
et al., 2008; Li et al., 2010). Furthermore, ketamine is effec-
tive in producing antidepressant-like effects in the LH in CMS-
treated mice at even a lower dose (3mg/kg) (Autry et al., 2011).
Currently, there is no information regarding the protracted effects
of ketamine in LH.
CHRONIC MILD STRESS (CMS)
Exposure to the CMS model induces depressive behavior in
rodents following the presentation of a series of stressors in an
unpredictable sequence over a prolonged period of time. CMS
produces a number of behavioral changes in rodents thought
to resemble features of depressed patients, such as anhedonia
or loss of grooming (Willner, 1997, 2005). CMS satisfies most
of the criteria of validity for an animal model of depression;
it is etiologically relevant with good design, resulting in similar
pathological alterations observed in humans that are sensitive to
chronic antidepressant treatment. The behavioral and molecular
changes induced by CMS are reversed by treatment with antide-
pressant drugs, but only after administration for several weeks.
In contrast, ketamine reversed the behavioral and physiological
alterations induced by CMS in rats following acute administra-
tion and the effects were maintained following chronic treatment.
Acute and chronic treatment with ketamine reversed the increase
in adrenal gland weight, promoted regain of body weight, and
normalized circulating corticosterone and ACTH levels (Garcia
et al., 2009). Physiological alterations induced by CMS were
reversed by acute ketamine treatment in a similar study but failed
to reverse CMS-induced anhedonia in the SPT (Rezin et al., 2009).
In addition, CMS-exposed adolescent rats exhibited decreased
immobility, increased sucrose consumption and latency to feed
immediately following acute ketamine treatment (Parise et al.,
2013).
Because the CMS is accepted as a rodent model of depres-
sion, CMS is an ideal paradigm with which to screen the
antidepressant-like effects of novel therapeutics like ketamine.
Reversal of CMS-induced depressive-like phenotypes measured
using the mouse FST, NSF, and SPT has been reported by
ketamine in the absence of any drug effect in stress naïve mice
(Autry et al., 2011). Furthermore, the effect of ketamine in the
NSF test was observed to persist in CMSmice 48 h post-injection.
In line with these findings, two similar studies have indicated an
increased sensitivity of CMS-exposed mice to ketamine (Li et al.,
2011; Ma et al., 2013). Taken together, the CMS data is the most
consistent and possibly the most valid method of examining the
antidepressant-like effects of ketamine in preclinical studies.
KETAMINE—MOLECULAR MECHANISMS OF ACTION
In order to develop novel and more effective antidepressants,
the molecular mechanisms underlying the protracted behavioral
improvement associated with ketamine treatment need to be
understood fully. The majority of this information has been gar-
nered from preclinical animal studies and the principle findings
are detailed in the following section.
NMDA AND AMPA RECEPTORS
Currently the hypothesis for ketamine’s mechanism of action
focuses on a cascade of neurochemical events that are initiated
shortly after administration of ketamine. The events then per-
sist in a protracted manner for days following its metabolism and
elimination.
Reductions in neurogenesis and synaptic plasticity play a key
role in the pathophysiology of MDD. Synaptic plasticity refers
to the dynamic capability of synapses to form and retract pro-
cesses, thereby modifying synaptic strength and communication.
The most well studied mechanisms mediating changes in plas-
ticity are long-term potentiation (LTP) and long-term depres-
sion (LTD). These processes involve significant alterations in
pre and post-synaptic scaffolding proteins and glutamate recep-
tors, primarily the glutamatergic receptor, α-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA). The AMPA receptor
containing the subunits GluR1, GluR4, and GluR2 are involved
in LTP, whereas GluR2, GluR3, and GluR4 are required for the
AMPA receptor internalization needed to facilitate LTD (Kessels
and Malinow, 2009). N-methyl-d-aspartate (NMDA) receptors at
excitatory synapses are also subject to trafficking and significantly
decrease in synaptic density during LTD (Peng et al., 2010). In the
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pyramidal cells of the hippocampus, LTP and LTD bidirectionally
regulate dendritic spine growth and retraction, whereas AMPA
expression is positively related to the size of the spine head. These
dynamic processes are stabilized by concurrent alterations in the
expression of synaptic proteins and signaling pathways.
Ketamine blocks NMDA receptors (NMDARs) at concentra-
tions of 2–50μm. The subsequent suppression of tonic gluta-
mate input to GABAergic interneurons, results in disinhibition
of glutamate signaling. This disinhibition and increase in gluta-
mate neurotransmission is mediated by a decrease in GABAergic
inhibitory feedback of the pyramidal neurons in layer V of the
PFC, a region widely implicated in the development of psychiatric
disorders (Homayoun and Moghaddam, 2007). Interestingly,
post-mortem studies report reductions in pyramidal cells and
GABAergic interneurons in the PFC of depressed individuals
(Choudary et al., 2005; Rajkowska et al., 2007). Increases in
glutamate will activate ionotropic AMPARs resulting in Na2+
influx and subsequent membrane depolarization, induction of
signaling cascades and protein synthesis. Certain AMPARs that
lack the GluR2 subunit actually result in Ca2+ influx (Kessels
and Malinow, 2009). Upregulation of AMPA receptor expression
following ketamine administration mediates the increased sen-
sitivity to glutamate. It has been suggested that this increased
sensitivity or “synaptic scaling” is necessary to maintain stabil-
ity in synaptic plasticity and increased protein synthesis in the
presence of chronic NMDAR blockade (Kavalali and Monteggia,
2012).
Pharmacological inhibition of ketamine’s behavioral effects
has been achieved using the AMPA receptor antagonist,
2, 3-dihdroxyl-6-nitro-7-sulfamoyl-benzo(f)quinoxaline-2, 3-
dione (NBQX), reversing the antidepressant effects of ketamine
in the LH paradigm (Maeng et al., 2008; Koike et al., 2011b).
Furthermore, co-administration of AMPAR antagonists blocked
the effects of ketamine in the FST (Autry et al., 2011). As
AMPARs have a clear role in mediating ketamine’s effects, a recent
study showed the antidepressant-like effect of AMPA administra-
tion in the depressive-like WKY rats (Akinfiresoye and Tizabi,
2013). This data indicate that AMPA receptors and indeed the
AMPA/NMDA ratio is an important consideration and target in
the development of potential therapeutics.
mTOR SIGNALING
Data suggests that the protracted antidepressant-like effects of
ketamine are mediated by molecular alterations to the signaling
pathway for the mammalian target of rapamycin (mTOR) (see
Figure 1), a serine/threonine kinase and key component of the
insulin-signaling pathway (Li et al., 2010). Two functional mTOR
complexes regulate the initiation of protein translation in mam-
malian cells, mTOR complex 1 (mTORC1) and mTOR complex
2 (mTORC2) (Rosner and Hengstschlager, 2011). A recent post-
mortem study implicated decreases in cortical mTOR-signaling
kinases in the pathophysiology of MDD (Jernigan et al., 2011).
Additionally, rats exposed to CMS exhibit significant reductions
in the phosphorylation of several kinases in the mTOR pathway
in the amygdala of stressed rats (Chandran et al., 2013).
There is an inverted U-shape associated with ketamine-
induced mTOR activation, with higher doses having no effect.
In rodents, ketamine administration induced mTOR signaling
approximately 30min after injection. Li and colleagues elucidated
some core features of ketamine’s mechanism of action, primarily
focusing on the alterations in mTOR dependent synapse forma-
tion in the PFC of rats (Li et al., 2010). In addition, they reported
increased phosphorylation of mTOR, p70 KD ribosomal protein
S6 kinase (p70S6K) and eukaryotic initiation factor 4E binding
protein 1 (4E-BP1). P70S6K is required to inhibit suppression
of eEF2, which prevents protein translation. Simultaneously, the
phosphorylation of 4E-BP1 results in the release of eukaryotic
translation initiation factor 4E (eIF-4E), thereby triggering the
initiation of translation of synaptic proteins. These changes were
accompanied by antidepressant-like behavior in the FST and NSF
test (Li et al., 2010).
mTOR is ubiquitously expressed and has been found to local-
ize in the cytoplasm of dendrites, where it can initiate the trans-
lation of synaptic proteins essential for the induction of LTP
(Duman et al., 2012). PSD95, GluR1 and synapsin are upregu-
lated approximately 2 h post-ketamine; this increase is observed
for up to 72 h. Similarly, upregulation of Arc, a cytoskeletal pro-
tein is observed approximately 1 h post-injection and sustained
for up to 6 h (Li et al., 2010). Arc is linked to the induction of
early and late phase LTP and memory formation (Panja et al.,
2009). A recent study confirmed that ketamine and MK-801
induced increases in immediate early genes, such as Arc, C-fos
and Homer1a. Homer1a/Homer1b/PSD-95 signaling is impli-
cated in glutamate induced synaptic plasticity (de Bartolomeis
et al., 2013) and may be an interesting marker of plasticity for
ketamine-like compounds. Similarly, reductions in the expres-
sion of eukaryotic elongation factor 2 (eEF2) is consistently
observed in rodents following ketamine administration both in
the PFC (Carrier and Kabbaj, 2013) and hippocampus (Autry
et al., 2011). Interestingly, females are more sensitive to the behav-
ioral effects of low dose ketamine compared to males; however,
females do not exhibit decreases in eEF2 (Carrier and Kabbaj,
2013). Nevertheless, phosphorylation and inhibition of eEF2 may
be a useful marker for rapid antidepressants, as increased phos-
phorylation of eEF2 in the PFC is also reported following chronic
fluoxetine treatment in rats (Dagestad et al., 2006).
Pharmacological modulation of different components of the
mTOR-signaling pathway (Figure 1) has been used to investi-
gate mechanisms underlying the acute and protracted behavioral
actions of ketamine. Inhibition of Akt, following blockade of
phosphatidylinositol-3-kinase (PI3K) by LY294002, and inhibi-
tion of ERK using U0126, prevented ketamine reversal of CMS-
induced deficits (Li et al., 2010). The Trk/B inhibitor K252a
blocked the effects of ketamine in the TST and the NSF when
tested 24 h, but not at 1 h (Koike et al., 2013b). The rapamycin-
FKBP12 complex inhibits mTOR signaling when directly bound
to mTORC1 (Hoeffer and Klann, 2010). Rapamycin pretreat-
ment inhibited both the molecular and behavioral effects of
ketamine on FST, NSF and the LH 24 h post-injection (Li et al.,
2010). Furthermore, rapamycin administration did not inhibit
the effects of ketamine in the NSF test at 30min post-injection,
but ketamine’s effects were completely blocked at 24 h post-
injection (Iijima et al., 2012). Thus, it appears that mTOR sig-
naling is clearly associated with the protracted behavioral effects
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FIGURE 1 | Following blockade of NMDARs, phosphorylation of Akt
activates mTOR complex 1 (mTORC1), which results in increased
p70S6K phosphorylation and increased protein translation via inhibition
of 4E-BP and release of eIF-4B. Glutamate binds AMPARs, which induces
depolarization of the membrane, enabling Ca2+ influx through VDCCs. This
results in BDNF release from synaptic vesicles. The subsequent binding of
TrkB receptors induces ERK and Akt signaling. These pathways all converge
to increase synaptic protein translation and receptor trafficking to the cell
membrane. Additionally, activation of mTORC2 by S6, and inhibition of GSK-3,
induces mTORC1 activation via increased Akt phosphorylation. Furthermore,
mTORC2 activation induces protein kinase C (PKC) signaling transduction,
which regulates actin and other cytoskeletal proteins.
of ketamine measured 24 h later or longer, but other mechanisms
may be involved in the immediate effects of ketamine, such as
increased AMPAR activation. It is of interest to note that other
antidepressants, including 5-HT2C receptor antagonists, citalo-
pram and electro-convulsive seizures (ECS, the equivalent to ECT
in rodents) all increase mTORC1 levels (Elfving et al., 2013;
Opal et al., 2013). However, the SSRI, sertraline, and the TCA,
imipramine, actually have anti-proliferative effects that are medi-
ated by inhibition of mTOR (Lin et al., 2010; Jeon et al., 2011).
Furthermore, there is evidence that suggests rapamycin adminis-
tration alone and the subsequent inhibition of mTOR signaling
is capable of inducing antidepressant-like effects in the rat FST
(Cleary et al., 2008). Moreover, the effects of long-term modu-
lation of mTOR have yet to be assessed. These data indicate the
role of mTOR signaling may be more complex than originally
anticipated.
Other drugs have been used to identify neural mechanisms
that might account for the antidepressant-like behavioral effects
of ketamine. NMDA receptor blockade using MK-801 or CPP
reduced immobility in the FST for up to 3 and 24 h, respectively,
but neither compound reproduced the protracted effects of
ketamine at longer intervals (Autry et al., 2011). The NR2B
antagonist RO-25-6981 was suggested to induce mTOR signal-
ing, resulting in similar molecular and behavioral effects as
those observed following ketamine administration (Maeng et al.,
2008; Li et al., 2010). In addition, the mGlu2/3 receptor antago-
nists LY341495 and MGS0039 decreased immobility time in the
TST. NBQX had a limited effect on these antagonists, whereas
rapamycin reversed the behavioral effects of these compounds at
24 h post-treatment, suggesting a role for mTOR signaling but not
AMPA in mediating the antidepressant-like effects of mGluR2/3
antagonists (Koike et al., 2011a). The mGluR5 antagonist MPEP
induced antidepressant-like effects in the NSF at 30min and
24 h post-injection (Iijima et al., 2012). The effects at 24 h were
blocked by rapamycin and the protein synthesis inhibitor ani-
somycin but not by the TrkB inhibitor K252a. In addition, the
mGluR7 agonist AMN082 produced an antidepressant like effect
in the TST 40min post-injection which was reversed by NBQX
pretreatment, suggesting that AMPA mediates the antidepressant
effects of this compound (Bradley et al., 2012). Finally, the glycine
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functional partial agonist GLYX-13 produced an antidepressant-
like effect in the FST, NIH and LH tests that extended for 24 h
after injection, similar to the effects of ketamine (Burgdorf et al.,
2013). These data suggest that when investigating the potential of
novel compounds targeting glutamate, both mTOR and AMPA
mediation should be assessed. Furthermore, it is important to
choose an appropriate rodent strain in which to conduct these
assays. For example, CD-1 mice are insensitive to modulation of
the glutamatergic system and the subsequent antidepressant-like
effects of AMNO82 and themGluR 7 negative modulatorMMPIP
(O’Connor and Cryan, 2013).
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)
Chronic administration of antidepressant drugs increases neu-
rotrophins including BDNF (Duman and Monteggia, 2006).
BDNF has high affinity for tyrosine kinase receptor B (TrkB),
activating a number of signaling pathways that regulate neuronal
growth and survival. This pathway also regulates the phosphory-
lation of cyclic-amp response element binding protein (CREB),
which is integral to affective behavior, in addition to learning
and memory (Autry and Monteggia, 2012). Post-mortem stud-
ies have reported reductions in BDNF and TrkB expression in
the hippocampus and PFC of MDD patients and depressed sui-
cides (Krishnan et al., 2007; Castren and Rantamaki, 2010; Yu
and Chen, 2011). Rodent models of chronic stress and depres-
sion have recapitulated these region-specific changes of BDNF
(Duman and Monteggia, 2006; Autry and Monteggia, 2012). At
a behavioral level, BDNF administration reduces immobility in
the FST (Shirayama et al., 2002; Hoshaw et al., 2005; Deltheil
et al., 2008). Additionally, the over-expression of TrkB recep-
tors leads to an antidepressant-like behavioral phenotype in mice
(Koponen et al., 2004). BDNF deficient mice are depressive-like
in some behavioral tests and fail to respond to conventional
antidepressants in the CMS and FST compared to wild type mice
(Saarelainen et al., 2003; Monteggia et al., 2007; Ibarguen-Vargas
et al., 2009).
Activation of the mTOR pathway by ketamine enhances trans-
lation of BDNF in the hippocampus (Garcia et al., 2008a; Autry
et al., 2011; Yang et al., 2012). The inhibition of eEF2 and subse-
quent increase in BDNF translation is proposed to mediate the
rapid antidepressant-like effects of ketamine (Monteggia et al.,
2013). Equally ketamine is capable of inducing a rapid release
of glutamate. Following NMDA receptor blockade, AMPAR acti-
vation results in calcium influx via L-type voltage gated calcium
channels (VDCC) inducing the release of BDNF from synaptic
vesicles (see Figure 1). Furthermore, BDNF regulates neuronal
mTOR function via Akt and PI3K, creating a positive feedback
loop of BDNF production following the activation of mTOR by
ketamine (Hay and Sonenberg, 2004; Hoeffer and Klann, 2010).
A single nucleotide polymorphism Val66Met (rs6265) in the
BDNF gene has been proposed as a potential impediment to the
antidepressant response to ketamine in TRD patients. Val/Val car-
riers are more sensitive to the antidepressant-effects of ketamine
compared to the Val/Met carriers (Laje et al., 2012). However, not
all studies have reported a positive correlation of improvement
in depressive symptoms with increased BDNF (Machado-Vieira
et al., 2009; Rybakowski et al., 2013). It is worth noting that BDNF
serum concentrations were significantly lower in bipolar patients
that did not respond to ketamine treatment compared to respon-
ders at baseline (Rybakowski et al., 2013). Mice that possess this
polymorphism did not respond to ketamine and displayed sig-
nificant impairments in synaptogenesis (Lindholm et al., 2012;
Liu et al., 2012). However, at higher doses, repeated dosing or
continuous infusion of ketamine, BDNF levels were increased,
although this increase was correlated with neurodegeneration and
cognitive deficits (Ibla et al., 2009; Goulart et al., 2010). Similarly,
humans who chronically abuse ketamine exhibit higher BDNF
concentrations compared to healthy controls (Ricci et al., 2011).
As a downstream product of multiple signaling cascades
induced by ketamine, the production of BDNF occurs rapidly
andmay underlie the protracted behavioral response to ketamine.
Indeed, acute i.c.v infusion of both BDNF and insulin-like growth
factor (IGF-1) are capable of mediating protracted antidepres-
sant like effects in the FST lasting up to 6 days following the
infusion (Hoshaw et al., 2008). These data not only indicate that
alterations in BDNF levels are most likely involved in the pro-
tracted effects of ketamine, but also confirms that rapid and
persistent increases in neurotrophins are useful markers of novel
rapid-acting antidepressants.
GLYCOGEN SYNTHASE KINASE-3 (GSK-3)
GSK-3 is a serine/threonine protein kinase and a major target for
the mood stabilizer lithium (Klein and Melton, 1996; Stambolic
et al., 1996). TRD patients are often given a period of antide-
pressant augmentation treatment with lithium when they fail
to response to SSRIs alone (Carvalho et al., 2007; Bauer et al.,
2010). Furthermore, studies have shown that GSK-3 is function-
ally regulated by serotonin modulation, primarily mediated by
5-HT1A autoreceptors and via iPI3K/Akt signaling (Polter et al.,
2012). GSK-3β± heterozygous mice display significant reductions
in immobility in the FST (O’Brien et al., 2004). Interestingly mice
with a knock-in mutation of GSK-3, which prevents its phos-
phorylation, do not respond to ketamine treatment in the LH
paradigm, suggesting that some of ketamine’s potential therapeu-
tic efficacy might be mediated following inhibition of this kinase
(Beurel et al., 2011). Furthermore, combination of ketamine
and the GSK-3 inhibitor, SB216763, significantly reduced immo-
bility in the FST; at a molecular level, this combination of
ketamine and SB216763 amplified the frequency of 5-HT and
hypocretin-induced EPSCs and increased spine density in the
mPFC. Conversely, it had been shown that ketamine has lim-
ited effects on GSK-3 expression in hippocampal synaptosomes
(Muller et al., 2013). Moreover, a single dose of ketamine reversed
the behavioral effects of CMS, but the GSK-3 inhibitor SB216763
had no effect on CMS-induced behavioral scores (Ma et al., 2013).
Further preclinical studies are required to evaluate the role of
GSK-3β in the antidepressant-like response to ketamine. A recent
assessment of three depressed patients indicates a significant
increase in phosphorylated GSK-3β in the plasma of ketamine-
treated individuals over the 120-min assessment period (Yang
et al., 2013a). Although the inhibition of GSK-3β modulates m-
TOR signaling (Figure 1) andmay potentially augment the effects
of antidepressants such as ketamine, it is unclear whether GSK-3
directly mediates the effects of ketamine.
www.frontiersin.org December 2013 | Volume 4 | Article 161 | 13
Browne and Lucki Antidepressant effects of ketamine
CONCLUSION AND FUTURE DIRECTIONS
The development of ketamine as a rapidly acting antidepres-
sant drug has the potential to revolutionize clinical treatment.
Nevertheless, the clinical use of ketamine for depression poses a
number of challenges. Ketamine is an hallucinogenic drug sub-
ject to abuse and must be given in a controlled setting. The effects
of ketamine are short-lasting and can only be sustained by its
repeated treatment. A desirable research direction would be to
develop other drugs with similar antidepressant effects that are
devoid of ketamine’s liabilities. However, progress in this area
is constrained by uncertainty concerning the critical pharma-
cological mechanisms underlying the antidepressant effects of
ketamine.
Animal models have the potential to translate the pharmaco-
logical effects of ketamine that are most critical for its clinical
antidepressant effects. A substantial body of literature now indi-
cates that ketamine produces antidepressant-like effects in pre-
clinical tests for antidepressant activity and in animal models of
depression. Acute ketamine produces immediate effects on many
behavioral tests that are similar to antidepressants. However, the
protracted effects of ketamine measured for days after a single
administration are not produced by conventional antidepressants.
They define a new paradigm for antidepressant drug discovery
that is the best temporal correlate with ketamine’s clinical activ-
ity. Inconsistent findings across laboratories may arise from a
disparity in methodology used across studies. The most perti-
nent variables are that the efficacious dose is dependent on the
behavioral task employed, conditions surrounding administra-
tion and the time of testing post-administration of ketamine. For
example, evidence suggests that the effects of low and seemingly
sub-efficacious doses of ketamine are more effective following
stress exposure. Behavioral tests with high predictive validity for
antidepressant-like effects, such as the FST, are sensitive to acute
and chronic ketamine. They can be utilized in conjunction with
other tests sensitive only to chronic antidepressant treatment,
such as the NSF/SPT, to measure the protracted benefits that are
unique to ketamine. Overall, combination of a stress or genetic
model of depression/anxiety with behavioral assessment over a
1–2 week period post-treatment with low doses of ketamine will
yield the most valid and useful information.
Among the many barriers to translation of ketamine’s clini-
cal antidepressant effects across species stand a number of key
pharmacological factors. The route of administration of ketamine
in preclinical models is by i.p. injection, whereas intravenous
infusion is usually employed in clinical trials. Therefore, it may
be beneficial for animal studies to employ intravenous infusion
where practical. In addition, plasma levels of ketamine mon-
itored in the first 2 h following administration can determine
whether the dose/route of administration of ketamine produces
comparable bioavailability across species. Given that the half-life
of ketamine is short, differing levels of ketamine may account
for some variation in the behavioral tests. However, ketamine is
no longer present when protracted behavioral effects are mea-
sured days after administration. These protracted changes result
from rapid and sustained molecular alterations induced follow-
ing a single treatment with ketamine. In addition, the preservative
benzethonium chloride (BCl) is universally used in ketamine
preparations both for clinical and preclinical use. Although
present in low concentrations, BCl can act synergistically with
ketamine to inhibit muscarinic and α7-nicotinic acetylcholine
receptors (Durieux and Nietgen, 1997; Coates and Flood, 2001).
The extent to which the additive properties of BCl on ketamine-
induced modulation of the cholinergic system may affect the
antidepressant-like response to ketamine is unknown. In the
present review, there was no systematic evidence that positive or
negative findings were associated with the source of ketamine in
the behavioral studies examined here (Tables 1, 2).
The mechanisms underlying ketamine’s effects, the simulta-
neous blockade of NMDA receptors and activation of AMPA
receptors, are integral for the induction of the antidepressant
response. The long-term consequences of these molecular alter-
ations are likely to mediate ketamine’s protracted antidepressant-
like effects mediated via increased synaptic plasticity, neuronal
survival and maturation. These changes occur within hours of
ketamine administration and occur in parallel with both the rapid
and protracted behavioral effects in animal models of depression.
The rapid modulation of mTOR, its downstream mediators, such
as Akt and ERK, and BDNF represent markers of the molecular
correlates of the antidepressant effects of ketamine and its abil-
ity to modify synaptic plasticity. Novel therapeutics for TRD are
likely to modulate these markers in a similar temporal pattern to
that of ketamine and can be used to identify better pharmaceutical
agents to treat TRD.
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